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Citrate inhibits growth of residual fragments in an in vitro model
of calcium oxalate renal stones.
Background. Alkaline citrate is thought to be helpful in re-
ducing recurrences of calcium oxalate stones. The evidence for
this is incomplete, there have been few good trials, all with their
own limitations, and not all reported any significant benefit. In
vitro studies are usually cited to support the clinical studies but
these too have their drawbacks, in particular they relate to crys-
tals and microscopic aggregates and not to actual stone growth.
Here we test citrate in vitro using a model of macroscopic cal-
cium oxalate stone enlargement.
Methods. Twelve calcium oxalate stones were grown at a time
in a stone farm. Six were grown with 2 mmol/L citrate and
six with 6 mmol/L citrate. Three protocols were tested; artifi-
cial urine, artificial urine with urinary macromolecules (UMM)
from male controls and artificial urine with UMM from male
stone formers. The stones were grown continuously for at least
24 days.
Results. In all three experiments the higher citrate concen-
tration significantly reduced the growth rate of stones by more
than 50% (P < 0.001). There was a small decrease in ionised
calcium in the stone growth media (P < 0.001) and significant
(P < 0.001) but small increase in pH (about 0.07 pH units).
The inclusion of UMM also brought about a decrease in stone
growth, particularly at 2 mmol/L citrate.
Conclusion. Citrate inhibited stone growth in this laboratory
model. This was true both in defined media and with addition
of UMM. This adds to evidence justifying the use of alkaline
citrate in calcium oxalate nephrolithiasis.
Urinary stone disease is a common urologic condition
that affects approximately 10% of the population at some
point in their lives [1]. In the majority of cases sponta-
neous passage of the stone will occur, but in about 25% of
cases some form of intervention is necessary. The advent
of lithotripsy and other minimally invasive techniques
has revolutionized the treatment of stones. Nevertheless,
these treatments only deal with the end result of an un-
derlying metabolic abnormality, which results in further
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recurrences in about 50% of patients [1]. Furthermore,
it is recognized that recurrences are higher when there is
incomplete removal of fragments following these proce-
dures [2–6].
Citrate is excreted in normal urine at a mean of about
3.3 mmol/day [7]. Its inhibitory effect on calcium oxalate
crystallization is generally recognized, the mechanism of
action being a reduction of calcium oxalate supersatura-
tion by forming complexes with calcium and direct inhi-
bition of crystal growth and aggregation. Such activities
might also be expected to prevent stone enlargement and
there has been recent interest in the use of citrate ther-
apy to prevent regrowth of the residual fragment. In one
study, Cicerello et al [8] demonstrated that alkaline citrate
therapy increases the clearance rate of residual fragments
in patients with calcium oxalate and infectious stones fol-
lowing extracorporeal shock wave lithotripsy (ESWL). In
another report, citrate therapy reduced post-ESWL re-
currence rates both in stone-free patients and those with
residual fragments [9]. Citrate therapy following ESWL is
also currently subject to a European multicenter trial and
this approach has been supported by recent evidence of
acute post-ESWL increases in lithogenic risk factors [10].
In vitro evidence favoring the use of citrate has been
derived from its inhibitory effect in calcium oxalate crys-
tallization studies. These experiments suffer from the dis-
advantage of being conducted on crystals only and rely
on the assumption that the results can be applied to ac-
tual stone growth. This is a questionable assumption and
has been described as a leap in faith [11]. Although stone
formation may begin with crystallization, it is known that
crystalluria occurs in healthy subjects with no evidence
of stones and many other distinctions between stones
and crystals can be drawn. For example, crystals are mi-
croscopic, form in seconds to minutes and millions will
arise almost simultaneously; stones, on the other hand,
are macroscopic, take months or years to form and arise
as discrete entities of just one or a few at a time. To
date there has been no direct experimental evidence to
link the processes behind crystallization and actual stone
growth. We have established a new technique of growing
macroscopic calcium oxalate stones in vitro, based on the
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mixed suspension mixed product removal system, [12,
13]. This model system (a stone farm) is ideal to test more
directly the effects of citrate on residual fragments.
METHODS
Three experimental protocols were followed; with ar-
tificial urine alone, artificial urine + urinary macro-
molecules (UMM) from male controls and artificial urine
+ UMM from male stone formers. In each protocol, six
stones were grown in 2 mmol/L citrate and another six
were grown in 6 mmol/L citrate.
The system was based on the stone generator recently
described by Ananth et al [12]. Further refinement and
expansion of the technique as a “stone farm” allows 12
stones to be grown simultaneously making controlled
studies feasible. This is fully detailed by Chow et al
[13]. Briefly, fragments of stones retrieved from a pa-
tient who had undergone percutaneous nephrolithotomy,
were adjusted to a dry weight of 100 ± 2 mg with abra-
sive paper. These fragments (primarily calcium oxalate
monohydrate with some brushite, by scanning electron
microscopy and x-ray diffraction) were suspended in in-
dividual jacketed crystallization chambers. Six pairs of
chambers were set up in parallel, the first of each pair
received two feed solutions at a total flow rate of ap-
proximately 1 L per day. The output of the first of the
pair of chambers was used as the feed for the second.
The two feed solutions make up an artificial urine with
calcium supplied by one feed line and oxalate by the
other. Feed solution I was made up of 12 mmol/L CaCl2,
6 mmol/L MgCl2 and 4 mmol/L K3citrate. Feed solu-
tion II contained 300 mmol/L NaCl, 151 mmol/L KCl,
40.4 mmol/L (NH4)2SO4, 10.2 mmol/L Na2HPO4, 38.8
mmol/L NaH2PO4, and 2.4 mmol/L Na2 oxalate (all
chemicals of analar grade, from VWR International, the
water was distilled and further purified to a resistivity
of 18 M-cm). When UMM were included, they were
added to the calcium-containing feed solution in such a
way that, within the crystallization chamber, the nomi-
nal concentration (without allowing for any losses during
preparation) was restored to the concentration in the na-
tive urine.
Artificial urine feed solutions were filter sterilized
(0.2 lm) into sterile bottles and stored at 4◦C for up to
8 days before use. When UMM were include, the bulk
calcium-containing feed solution was made up to half
the volume with water and, on a daily basis, made up to
strength with the UMM. NaN3 was added to the calcium-
containing feed solutions at 0.04% just prior to use.
Flow rates were checked daily by the change of weight
of the feed solutions over time. The solutions within each
chamber were continuously stirred and the temperature
controlled at 37◦C. The volume of solution in each cham-
ber was set at 20 mL.
Every 24 hours the stones were removed and the sys-
tem cleaned with 0.1 mol/L HCl. Stones were weighed
approximately every other day, and the pH and ionized
calcium ([Ca2+]) of each individual chamber were mea-
sured regularly by ion selective electrodes.
Urine was obtained from recurrent male calcium stone
formers with no recognized metabolic pathology such as
primary hyperparathyroidism or primary hyperoxaluria
or healthy male controls with no history of stone disease.
Twenty-four–hour samples were collected in plastic con-
tainers to which 3 mL of Hibitane (AstraZeneca, Mac-
clesfield, UK) (contains 5% chlorhexidine gluconate) was
added. All samples showed no more than a trace of blood
and were negative for leucocytes and nitrite by dipstick
test (Multistix SG; Bayer, Newbury, UK). One or two
consecutive 24-hour samples from a few individuals were
pooled for processing in batches of between 8 and 10 L.
After centrifugation (2500g, 10 minutes) and sieving
(20 lm nylon net) (Millipore) UMM were isolated by tan-
gential flow diafiltration using 5 kD cut off membranes
(5 K Omega Centramate medium screen; Pall Corpora-
tion, VWR International, Poole, UK). Two or five mem-
brane cassettes, each 0.93 m2 were used. Conductivity
was monitored with an in-line conductivity detector
(Oakton-100 series, USA). Apart from the ultrafiltration
membrane all wetted surfaces were polypropylene or
stainless steel. The urine was pumped through the sys-
tem (feed pressure 40 psi, transmembrane pressure 20
to 25 psi) until its volume was reduced to approximately
one fourth of the starting volume. Water was then drawn
into the system (diafiltration) until the conductivity fell
to ≤1 mS/cm. The final volume was adjusted to exactly
one fourth of the starting volume by further filtration or
water addition and the product stored at −20◦C. In eight
production batches, the protein content of the product av-
eraged 140 lg/mL, compared to 70 lg/mL in the starting
material. Low-molecular-weight material was effectively
removed and this would contribute ≤0.7 mmol/L cal-
cium, ≤0.2 mmol/L sodium, ≤0.005 mmol/L oxalate, and
≤0.1 mmol/L citrate to the contents of the crystallizer
chambers.
Stone weights were plotted against the experiment du-
ration. Cross sectional areas of the stones before and after
the experiment were estimated from photographs using
a graphics tablet and diameters calculated as though this
area was a circle.
Statistical comparisons of weights, chamber pH and
chamber [Ca2+] over time (within-subjects variables),
distinguishing between different chambers and citrate
concentration (between subjects factors) were performed
using a general linear model with repeated measures
(SPSS, version 10.1). Individual stone growth rates were
estimated by linear regression. Growth rates, initial and
final stone weights, and changes in diameter were com-
pared by Mann-Whitney U tests.
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Table 1. Details of stone growth in three experiments
Artificial urine + UMM Artificial urine + UMM
Artificial urine (male controls) (male stone formers)
Duration hours 671 593 985
End weight mg ± SE
2 mmol/L citrate 294.0 ± 28.8 169.9 ± 9.5 189.3 ± 4.6
6 mmol/L citrate 141.6 ± 4.1 127.2 ± 3.9 141.8 ± 8.5
P value 0.004 0.010 0.004
Changes in diameter mm ± SE
2 mmol/L citrate 3.48 ± 0.48 1.30 ± 0.14 1.10 ± 0.11
6 mmol/L citrate 0.88 ±.013 0.61 ± 0.17 0.91 ± 0.36
P value 0.004 0.025 0.522
Growth rate mg/hour ± SE
2 mmol/L citrate 0.289 ± 0.045 0.117 ± 0.016 0.088 ± 0.004
6 mmol/L citrate 0.063 ± 0.006 0.041 ± 0.006 0.036 ± 0.008
P value 0.004 0.001 0.001
UMM is urinary macromolecules. Each experiment consisted of six stones grown in 2 mmol/L citrate and six grown in 6 mmol/L citrate. Initial weights were
approximately 100 mg and did not differ (P > 0.05) between 2 and 6 mmol/L citrate. Because the growth period differs for each experiment, the end weights and
diameter changes should only be compared within each column.
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Fig. 1. Mean weight of stones (±SE) over time, grown in artificial urine
with 2 mmol/L citrate () or with 6 mmol/L citrate (). P < 0.001.
RESULTS
The final weights, growth rates, and diameters for the
stones grown in control urine (2 mmol/L citrate) and for
those grown in 6 mmol/L citrate with the three different
protocols are shown in Table 1. Stones had a significantly
lower growth rate and attained a smaller size over time,
when grown in 6 mmol/L citrate than in control urine
(Figs. 1 to 4). Growth rates were also lower when UMM
were included in the artificial urine. This was most notice-
ably when the citrate concentrations was 2 mmol/L (0.289
mg/hour vs. 0.117 mg/hour and 0.088 mg/hour for artifi-
cial urine, artificial urine + UMM from male controls, and
artificial urine + UMM from male stone formers, respec-
tively (P = 0.004) (Fig. 5). The difference between stones
grown in artificial urine and artificial urine + UMM was
less but still significant at 6 mm citrate (P = 0.037) (Fig. 6).
At both citrate concentrations, there was no apparent
difference in the growth rate between the stones grown
with the addition of UMM from male controls to those
with the addition of UMM of stone formers (P > 0.05)
(Figs. 5 and 6).
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Fig. 2. Mean weight of stones (±SE) over time, grown in artificial urine
and urinary macromolecules of male controls with 2 mmol/L citrate ()
or with 6 mmol/L citrate (). P < 0.001.
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Fig. 3. Mean weight of stones (±SE) over time, grown in artificial urine
and urinary macromolecules of male stone formers with 2 mmol/L cit-
rate () or with 6 mmol/L citrate (). P < 0.001.
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Fig. 4. Examples of stones before and after growth in three experiments with 2 mmol/L (left two columns) or 6 mmol/L (right two columns) citrate.
Grids are 5 × 5 mm. Abbreviations are AU, artificial urine; UMM, urinary macromolecules.
The average [Ca2+] concentrations for the duration of
the experiment were significantly higher for those cham-
bers housing the stones grown in control urine compared
with those grown in 6 mmol/L citrate urine (P < 0.001).
The pH of control chambers was slightly higher than that
of the 6 mmol/L citrate chambers (Table 2).
By scanning electron microscopy and x-ray diffraction,
the composition of the product grown was consistent with
the salt composition of the artifical urine (i.e., calcium
oxalate, as the monohydrate, and some brushite). The
proportion of brushite appeared to be reduced in stones
grown in 6 mmol/L citrate.
DISCUSSION
Hypocitraturia is a frequent finding among patients
with urinary stone disease, with a reported occurrence of
19% to 63% [7]. Together with the calcium complexing
ability of citrate and in vitro evidence of its calcium ox-
alate crystallization inhibition [14] this has been used to
justify a number of trials of citrate therapy in an attempt
to prevent stone recurrences in hypocitraturic conditions
associated with urolithiasis [15–18]. More recently the
beneficial effects of citrate has been proposed to extend
to normocitraturic stone formers [19], and there has also
been interest in its use to prevent recurrences following
minimally invasive procedures [8, 9].
All of the above evidence in favor of a beneficial ef-
fect of citrate on calcium-stone recurrence can easily be
challenged by a determined Devil’s advocate. The high
incidence of hypocitraturia reported by some may reflect
their choice of cutoff values, which range from <2 mmol/
day [20] to <1.69 mmol/day [7] while it has been reported
that 10% of normal men excrete <1.85 mmol/day and
10% of normal women excrete <1.75 mmol/day [14]. In
one study of three large cohorts there was no difference
in urinary citrate excretion between stone formers and
controls, nor was there an inverse relationship between
urinary citrate and the risk of stone formation [21]. The
calcium complexing ability of citrate is real, but under
physiological conditions will only be modest. For our ar-
tificial urine, at 6 mmol/L calcium, 0.3 mmol/L oxalate,
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Fig. 5. Mean weight of stones (±SE) over time, grown in artificial urine
(), artificial urine with urinary macromolecules of male controls ()
and artificial urine with urinary macromolecules of male stone formers
(o) in 2 mmol/L citrate with vs. without urinary macromolecules. P =
0.004.
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Fig. 6. Mean weight of stones (±SE) over time, grown in artificial urine
(), artificial urine with urinary macromolecules of male controls ()
and artificial urine with urinary macromolecules of male stone formers
(o) in 6 mmol/L citrate with vs. without urinary macromolecules. P =
0.037.
pH 6.0, a 300% increase in citrate from 2 to 6 mmol/L
produces a 23% fall in calculated calcium oxalate super-
saturation. Much of the in vitro evidence of an effect of
citrate on crystallization was obtained in defined media
without the presence of urine and, as we have argued,
crystals are not the same as stones. The clinical evidence
for a beneficial effect of citrate therapy is not as com-
plete as one might like with inadequacies in randomiza-
tion, controls, patient selection, patient numbers, time of
follow up, outcome measures, and compliance. The vari-
ability in study design and study population precluded
adequate analysis of alkali citrate in a meta-analysis of
randomized trials [22] and only two of five prospective
randomized trials reported positive findings [23].
There are many difficulties in performing good trials
into prevention of calcium stone disease [23] but this em-
phasizes the need for further laboratory studies, which
can contribute to the body of evidence on the potential
value of citrate therapy. Our model of stone growth, while
not itself immune from all criticism, is very different from
all that has gone before. It is based on a recognized prin-
ciple, mixed suspension mixed product removal [11], is
statistically powerful and robust [13] and addresses some
of the deficiencies of other in vitro studies [12].
The results from our experiments showed that citrate
at a concentration of 6 mmol/L was highly effective at
inhibiting residual fragment growth (>50% reduction in
growth rate). Previously Suzuki, Tsugawa, and Ryall [24]
showed in vitro that sodium potassium citrate inhibited
the nucleation and growth of calcium oxalate stones onto
the surface of fragmented kidney stones. Their experi-
ments were conducted over a period of 3 hours, at room
temperature with artificial urine as the sole substrate. Our
experiments were conducted over a longer period of time
and in simulated physiologic media and conditions to re-
flect (albeit imperfectly) more closely the in vivo bio-
logic processes. In an in vivo rat model, citrate was found
to reduce the extent of deposition of calcium oxalate
in the kidney [25], but individually, these deposits were
microscopic.
Biologic urine contains various high-molecular-weight
compounds such as proteins and glycosaminoglycans,
which have been shown to play an important role in stone
formation. Investigators have shown that certain individ-
ual macromolecules as well as UMM collectively inhibit
crystal growth and aggregation in vitro, an effect that has
been attributed to the adsorption of these compounds on
to the surface of crystals hindering further deposition or
binding of other crystals [26–33].
The artificial urine used in some experiments lack these
macromolecules contained in biologic urine and is there-
fore a poor reflection of in vivo conditions. In contrast,
using whole urine, although addressing this issue would
result in a variable ionic environment. Our results in-
cluded experiments conducted with artificial urine sup-
plemented with UMM from male controls and male stone
formers. This allowed simulation of biologic urine yet
maintaining a constant ionic composition. A potential
problem with UMM is that losses of important material
may have occurred during production. It is recognized
that centrifugation or filtration will remove some urinary
material, particularly Tamm-Horsfall protein. Our quan-
titative estimates of protein recovery show that some
losses do occur and gel electrophoresis (data not shown)
demonstrates that the usual urinary protein profile per-
sists, with some diminution of the Tamm-Horsfall protein
band. The use of UMM should be seen as the best compro-
mise between a defined artificial urine and whole urine
which is variable and uncontrolled. The independent
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Table 2. Mean ionized calcium and pH in the crystallization chambers during three experiments
Artificial urine + UMM Artificial urine + UMM
Artificial urine (male controls) (male stone formers)
[Ca2+] mmol/L ± SE
2 mmol/L citrate 2.06 ± 0.03 2.21 ± 0.12 2.43 ± 0.05
6 mmol/L citrate 1.43 ± 0.08 1.71 ± 0.08 1.62 ± 0.03
P value <0.001 <0.001 <0.001
pH ± SE
2 mmol/L citrate 6.02 ± 0.01 5.98 ± 0.01 6.00 ± 0.002
6 mmol/L citrate 6.09 ± 0.02 6.07 ± 0.01 6.06 ± 0.001
P value <0.05 <0.001 <0.001
UMM is urinary macromolecules. These represent the equilibrium values achieved in the crystallisers, during the course of each experiment, both of these variables
are essentially constant (P > 0.05). Each experiment consisted of six stones grown in 2 mmol/L citrate and six grown in 6 mmol/L citrate.
inhibitory effect of UMM was demonstrated in our study
on macroscopic stone growth, particularly at 2 mmol/L
citrate. Greater inhibition by macromolecules from non-
stone formers as compared to stone formers has also been
a feature of previous studies [26–33] but the results ob-
tained over the series of experiments reported here did
not support this. Our technique is best suited to com-
parisons within individual experimental arms and com-
parisons across experiments should be treated cautiously
until we have further experience on the long term consis-
tency of the stone farm (initial result across a number of
control experiments are encouraging). Comparisons be-
tween UMM from stone formers and nonstone formers
on macroscopic stone growth certainly warrant further in-
vestigation. The present study was conducted with UMM
from males only and future studies with UMM from the
female population would also be of interest.
The lower [Ca2+] for the chambers in the 6 mmol/L cit-
rate arm of the study is consistent with the mechanism of
citrate complexation with calcium, which resulted in an
inhibitory effect as a consequence of the reduction in the
relative calcium oxalate supersaturation ratio. The direct
effects of citrate on growth and agglomeration could not
be isolated from the supersaturation change in these par-
ticular sets of experiments. Although there was a slight
increase of the pH in the 6 mmol/L citrate arm, as a result
of a larger alkali addition to the feed solution, this was
too small to independently cause any significant effect on
growth. When potassium citrate is administered orally,
the urinary pH is increased as a result of the alkali load
supplied to the body. In addition to reducing the calcium
oxalate crystallization process independently, this rise in
urinary pH further increases the urinary citrate excretion
by reducing its reabsorption in the proximal tubules [7].
In fresh artificial urine, with oxalate omitted, [Ca2+]
was 2.85 mmol/L compared to the dynamic equilibrium
value of 2.06 mmol/L during the stone growth experi-
ment. This difference (28%) reflects the suspended pre-
cipitate as well as any precipitated being incorporated
into the stone. An indication of the calcium consumption
into the stones can be estimated from the growth rates.
The highest of these, nearly 0.3 mg/hour, corresponds to
about 2 mg of calcium per day (if the product is pure cal-
cium oxalate monohydrate). As we are pumping about
240 mg of calcium per day past each stone only a small
proportion of the precipitated or total calcium is being in-
corporated into the stone. Applying the same reasoning
to oxalate consumption, about 4% of available oxalate
was incorporated into the control (2 mmol/L citrate)
stones grown in artificial urine (compared to approxi-
mately 5% reported previously [13]).
The significant inhibitory effect of a higher urinary cit-
rate concentration on stone fragment growth in this study
provides more direct evidence and reinforces the use of
citrate in reducing stone recurrences and residual frag-
ment growth.
The higher citrate concentration of 6 mmol/L used in
this study is physiologically realistic for 24-hour urines
of 1 to 1.5 L, although most patients taking oral citrate
supplementation attain a more modest concentration de-
spite receiving the full therapeutic dose [15–19]. Oral cit-
rate preparations do have recognized side effects, notably
causing gastrointestinal irritation in 9% to 17% of pa-
tients [15, 19]. Together with lengthy asymptomatic peri-
ods this has contributed to a lack of long term compliance,
as highlighted in one study when half of the subjects failed
to take the drug continuously for 3 years [19]. Strength-
ening the evidence base for the use of citrate therapy in
recurrent calcium oxalate stone formers might help to im-
prove compliance. Our findings suggest that therapeutic
use of citrate could significantly prolong (more than dou-
ble) the symptom-free period between stone episodes.
We believe our results are more relevant than most
previous in vitro studies and add new and significant data
supporting the use of citrate to prevent or slow stone
growth.
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